Sachin Kumar, PhD
Sachin Kumar, PhD
Scientist, Dept. of Medical Oncology, Dr BRA-IRCH, All India Institute of Medical Sciences
Verified email at aiims.ac.in - Homepage
Title
Cited by
Cited by
Year
Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool
AK Pathak, M Bhutani, S Kumar, A Mohan, R Guleria
Clinical chemistry 52 (10), 1833-1842, 2006
2482006
Targeting Mcl-1 for the therapy of cancer
BA Quinn, R Dash, B Azab, S Sarkar, SK Das, S Kumar, RA Oyesanya, ...
Expert opinion on investigational drugs 20 (10), 1397-1411, 2011
2122011
Biomarkers in cancer screening, research and detection: present and future: a review
S Kumar, A Mohan, R Guleria
Biomarkers 11 (5), 385-405, 2006
1332006
A common medical error: lung cancer misdiagnosed as sputum negative tuberculosis
VK Singh, S Chandra, S Kumar, G Pangtey, A Mohan, R Guleria
Asian Pac J Cancer Prev 10 (3), 335-8, 2009
662009
Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer
A Mohan, P Singh, S Kumar, C Mohan, AK Pathak, RM Pandey, R Guleria
Asian Pac J Cancer Prev 9 (4), 557-62, 2008
612008
Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy
S Kumar, R Guleria, V Singh, AC Bharti, A Mohan, BC Das
Lung cancer 70 (2), 211-217, 2010
512010
Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer
S Kumar, R Guleria, V Singh, AC Bharti, A Mohan, BC Das
European Respiratory Journal 36 (4), 885-892, 2010
452010
Prognostic implications of circulating anti‐p53 antibodies in lung cancer–a review
S Kumar, A Mohan, R Guleria
European journal of cancer care 18 (3), 248-254, 2009
392009
Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer
S Kumar, R Guleria, A Mohan, V Singh, AC Bharti, BC Das
Cancer investigation 29 (3), 202-207, 2011
292011
Plasma Nucleosome Levels Might Predict Response to Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
S Kumar, R Guleria, V Singh, AC Bharti, A Mohan, BC Das
Clinical lung cancer 11 (1), 36-44, 2010
282010
Association of functionally important polymorphism of microsomal epoxide hydrolase gene (EPHX1) with lung cancer susceptibility
AR Tilak, S Kumar, M Jain, MC Pant, BC Das, R Guleria, B Mittal, ...
Cancer investigation 29 (6), 411-418, 2011
272011
Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance
AA Bhat, SN Younes, SS Raza, L Zarif, S Nisar, I Ahmed, R Mir, S Kumar, ...
Molecular cancer 19 (1), 1-21, 2020
242020
Epigenetic regulators of programmed death-ligand 1 expression in human cancers
S Kumar, SK Sharawat
Translational Research 202, 129-145, 2018
212018
Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer
S Kumar, R Guleria, V Singh, AC Bharti, A Mohan, BC Das
BMC cancer 9 (1), 1-12, 2009
192009
Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non–small cell lung cancer patients
S Kumar, SK Sharawat, A Ali, V Gaur, PS Malik, S Kumar, A Mohan, ...
Current problems in cancer 44 (4), 100540, 2020
182020
Regulation of expression of microRNAs by DNA methylation in lung cancer
SK DK Singh, S Bose
Biomarkers, 2016
122016
Role of microRNA in regulating cell signaling pathways, cell cycle, and apoptosis in non-small cell lung cancer
SK DK Singh, S Bose
Current Molecular Medicine, 2016
122016
Utility of plasma tumour necrosis factor-α and transforming growth factor-β1 as predictors of survival and treatment outcome in advanced non-small cell lung carcinoma
S Kumar, R Guleria, A Mohan, V Singh, A Ali, AC Bharti, BC Das
Biomarkers 15 (5), 446-453, 2010
102010
Polymorphism Arg72Pro of p53 confers susceptibility to squamous cell carcinoma of lungs in a North Indian population
AR Tilak, S Kumar, MC Pant, N Mathur, A Kumar
DNA and cell biology 32 (2), 66-72, 2013
92013
PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix
M Mann, S Kumar, A Sharma, SS Chauhan, N Bhatla, S Kumar, S Bakhshi, ...
Oncotarget 10 (42), 4262, 2019
82019
The system can't perform the operation now. Try again later.
Articles 1–20